Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H14F3N3O3 |
| Molecular Weight | 389.328 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)N(C(=O)[C@@]1(CO)C2=CC=CC=C2)C3=CC=C(C#N)C(=C3)C(F)(F)F
InChI
InChIKey=VAJGULUVTFDTAS-GOSISDBHSA-N
InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1
| Molecular Formula | C19H14F3N3O3 |
| Molecular Weight | 389.328 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:39:51 UTC 2023
by
admin
on
Sat Dec 16 10:39:51 UTC 2023
|
| Record UNII |
8O59X1ACZT
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
8O59X1ACZT
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY | |||
|
59317190
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY | |||
|
DB12461
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY | |||
|
300000041491
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY | |||
|
GLPG-0492
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY | GLPG0492 has very good pharmacokinetic properties, including bioavailability in rat (F > 50%), and is currently under evaluation in phase I clinical trials. GLPG0492 is a new non-steroidal selective androgen receptor modulator that is currently under development for musculo-skeletal diseases such as sarcopenia and cachexia. In acute exhaustion tests, a surrogate of the 6-min walking test used in DMD patients, GLPG0492 preserved running performance, whereas vehicle- or comparator-treated animals showed a significant increase in fatigue (30-50%). GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis. | ||
|
1215085-92-9
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL3545417
Created by
admin on Sat Dec 16 10:39:51 UTC 2023 , Edited by admin on Sat Dec 16 10:39:51 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Official Title: Assessment of the Muscle Protein Fractional Synthesis Rate Induced by Repeated Administrations of GLPG0492 to Healthy Male Subjects and Assessment of the Safety, Tolerability and Pharmacokinetics of Repeated Administrations of GLPG0492 to Healthy Postmenopausal Women.
Purpose: GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g. after orthopedic surgery) or due to aging (androgenic effect), but without anabolic effects (e.g. effect on testosterone). In the first part of the current study it will be tested whether GLPG0492 given orally to healthy male volunteers increases the protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine.
|
||
|
ACTIVE MOIETY |
Purpose: GLPG0492 is a selective androgen receptor modulator: the compound should help protect against (or help restore) muscle loss in case of immobilization (e.g. after orthopedic surgery) or due to aging (androgenic effect), but without anabolic effects (e.g. effect on testosterone). In the first part of the current study it will be tested whether GLPG0492 given orally to healthy male volunteers increases the protein synthesis in muscle, as measured by the uptake into the muscle of intravenously infused phenylalanine.
|
||
|
ACTIVE MOIETY |
Originator: ProSkelia; Developer: Akashi Therapeutics, Galapagos NV; Class: Small molecule; Mechanism of Action: Selective androgen receptor modulator; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Preclinical for Duchenne muscular dystrophy, Discontinued for Cachexia; Most Recent Events: 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (PO), 24 Jun 2014 DART Therapeutics is now called Akashi Therapeutics, 20 Mar 2013 DART Therapeutics plans a phase IIa trial in Healthy volunteers
|
